Kintegral Advisory’s Alexion Pharmaceuticals ALXN Stock Holding History

Kintegral Advisory’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-2,193	Closed	-$214K	–	302
2018 Q4	$214K	Buy	+2,193	New	+$259K	0.06%	216

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Kintegral Advisory's ALXN Position: Q1 2019 in Review

Kintegral Advisory sold out of Alexion Pharmaceuticals (ALXN) in Q1 2019, closing a stake of 2,193 shares — an estimated $214K sold.

Kintegral Advisory first reported a position in ALXN in Q4 2018 and held it in 1 quarter. The position peaked at $214K in Q4 2018. 611 funds tracked by Wall St. Rank hold ALXN as of Q1 2019.

Kintegral Advisory reported no remaining Alexion Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Kintegral Advisory sold 2,193 Alexion Pharmaceuticals shares in Q1 2019, an estimated $214K.
Kintegral Advisory first reported a position in Alexion Pharmaceuticals in Q4 2018 and held it in 1 quarter.
Kintegral Advisory's Alexion Pharmaceuticals position peaked at $214K in Q4 2018.
611 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2019.

Based on Kintegral Advisory's 13F filing for Q1 2019, filed 15 May 2019.